Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma.
about
Antisense-induced down-regulation of thymidylate synthase and enhanced cytotoxicity of 5-FUdR in 5-FUdR-resistant HeLa cellsRecent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family.A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors.Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective.PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation.Specific down regulation of 3T3-L1 adipocyte differentiation by cell-permeable antisense HIF1alpha-oligonucleotide.HER2/neu antisense targeting of human breast carcinoma.How apoptosis is regulated, and what goes wrong in cancerPotential roles of antisense technology in cancer chemotherapy.Antisense oligonucleotide against hTERT (Cantide) inhibits tumor growth in an orthotopic primary hepatic lymphoma mouse model.Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system.Gene therapy for the treatment of oral squamous cell carcinoma.Induction of apoptosis in cancer: new therapeutic opportunities.Small molecule inhibitors of bcl-2 family proteins for pancreatic cancer therapyRational design and rapid screening of antisense oligonucleotides for prokaryotic gene modulation.RAF antisense oligonucleotide as a tumor radiosensitizer.Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.The Bcl-2 family: roles in cell survival and oncogenesis.Apoptosis as a tool for therapeutic agents in haematological diseases.Death receptors in chemotherapy and cancer.Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphomaAdvances in the development of therapeutic nucleic acids against cervical cancer.Inhibitor of apoptosis proteins: new therapeutic targets in hematological cancer?Targeted therapy for hematologic malignancies.Antisense therapy for cancer.Inhibition of MicroRNA-21 induces apoptosis in dermal fibroblasts of patients with systemic sclerosis.Mitochondria: pharmacological manipulation of cell deathInhibitory effects of antisense RNA of HAb18G/CD147 on invasion of hepatocellular carcinoma cells in vitro.RNA interference for treating haematological malignancies.BCL2 family of apoptosis-related genes: functions and clinical implications in cancer.Epstein-Barr virus interactions with the Bcl-2 protein family and apoptosis in human tumor cells.Delivery of intracellular-acting biologics in pro-apoptotic therapies.Bcl-2 expression predicts radiotherapy failure in laryngeal cancerNeed for an improved molecular/genetic classification for CD30+ lymphomas involving the skin.Oblimersen in the treatment of metastatic melanoma.Downregulation of KSR1 in pancreatic cancer xenografts by antisense oligonucleotide correlates with tumor drug uptake.Potential use of custirsen to treat prostate cancer.Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.
P2860
Q28365365-F8E79266-BD90-491C-A236-67465067A2C9Q30971455-DB40A746-5F89-462F-AD21-04E001547F5FQ33379466-8E31DFCA-FB0F-448A-899B-44D07FBB5756Q33392920-93A4D911-1142-4FE5-80A4-C61700542FC3Q33418637-A8B20C34-576D-4CE2-9883-EBDD0AC8BDC0Q33767159-83FBC0CE-BDA0-416B-A5BB-75EE653C4886Q33823337-7CFF7D29-0A31-45E8-8752-9BBE9A6759A8Q34130563-6327B93F-1BAA-45E1-B197-9A1BDC23ED20Q34290061-D4CB3216-D898-46D8-ADA4-98710758512CQ34293601-DAED9CE7-7C79-43A4-9240-30C91FA95D46Q34358498-D54F769F-7C6E-4DDB-B492-793C40BD4DFCQ34366036-6C217BAC-FBF3-459F-B29A-10AC3C51258EQ35036732-DC93206A-1E22-473F-9110-AF0D331E207DQ35043420-86BD62D7-2845-4778-89A5-B943FAD403B9Q35099238-1DF1FCB4-3952-4214-9887-26B00DF3D41EQ35130605-82D50EE0-DF64-4E8C-A0CE-2C7C9CDC9B65Q35208827-4AEA57F3-A5AB-42C7-ACB4-9525199C5A7EQ35222636-37B67FF9-4DA9-4018-AD5D-DC49272D752DQ35591695-71D56191-7B74-4E20-8D26-CE5F4522929FQ35684882-BA92AC98-316B-485A-9573-4D1036630BCCQ35743149-94F812AF-4001-4C2A-AEA3-63F39CE96CE8Q35797583-714C0D63-A44B-4C7E-9AEF-409A0A481F01Q35842608-6F323F81-51B4-4E31-954C-179D2E386B14Q35905166-A75DD571-2F71-43C7-99DC-E4F019E49926Q36108610-5E272AEF-8840-4407-A775-23D8A23098A0Q36133133-6E1F4EDD-7180-48B4-B269-575DD102BC0CQ36135895-C03404DE-9C9E-4D1A-BDB1-5EB2FD11CC39Q36274960-7CF2B5FE-374B-4D71-83C8-B03F70BE6731Q36308635-1721CB69-6494-4041-A47B-3470EC1B8379Q36327055-E1956F24-140E-4482-80BC-DD896768A80BQ36419013-FCCCA1C3-FBA0-4C31-826B-89375F747A43Q36526103-263C3929-50E7-4853-A5AB-C6E7D16A65ECQ36588920-749174AD-A567-4F8C-8DAC-A5B51682BBBEQ36616047-B304C23A-336A-4A38-8699-5292C364432BQ36771224-D66FE644-6934-499F-8140-EE16F6FE583EQ36839762-413A0B21-5637-44FE-BD28-D24511A38BCCQ36957167-C64B4AD3-C81B-45C9-BA8A-6D3C76A3A3AFQ36975969-57BCD052-5D97-4AD8-8D42-B3683FB763ADQ37120213-3A59EA89-54C2-47CE-AAB0-2283A29BB60AQ37178611-6BFAF6C0-D7D2-4B81-A348-82A1CAFB3002
P2860
Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Phase I clinical and pharmacok ...... s with non-Hodgkin's lymphoma.
@ast
Phase I clinical and pharmacok ...... s with non-Hodgkin's lymphoma.
@en
Phase I clinical and pharmacok ...... s with non-Hodgkin's lymphoma.
@nl
type
label
Phase I clinical and pharmacok ...... s with non-Hodgkin's lymphoma.
@ast
Phase I clinical and pharmacok ...... s with non-Hodgkin's lymphoma.
@en
Phase I clinical and pharmacok ...... s with non-Hodgkin's lymphoma.
@nl
prefLabel
Phase I clinical and pharmacok ...... s with non-Hodgkin's lymphoma.
@ast
Phase I clinical and pharmacok ...... s with non-Hodgkin's lymphoma.
@en
Phase I clinical and pharmacok ...... s with non-Hodgkin's lymphoma.
@nl
P2093
P1476
Phase I clinical and pharmacok ...... s with non-Hodgkin's lymphoma.
@en
P2093
P304
P356
10.1200/JCO.2000.18.9.1812
P407
P577
2000-05-01T00:00:00Z